Drug Profile
Vebreltinib - Apollomics/Beijing Pearl Biotechnology
Alternative Names: APL-101; Bozitinib - Apollomics/Beijing Pearl Biotechnology; Bozitinib - Beijing Pearl Biotechnology/CBT Pharmaceuticals; CBI-3103; CBT-101; PLB-1001Latest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator Crown Bioscience
- Developer Apollomics; Beijing Pearl Biotechnology
- Class Antineoplastics; Cyclopropanes; Fluorinated hydrocarbons; Indazoles; Pyrazoles; Pyridazines; Small molecules; Triazoles
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Registered Non-small cell lung cancer
- Preregistration Glioblastoma
- Phase II Solid tumours
- Phase I/II Liver cancer; Renal cell carcinoma
Most Recent Events
- 28 Mar 2024 Beijing Pearl Biotechnology completes a phase II/III trial in Glioblastoma (Recurrent) in China (PO) before March 2024 (NCT06105619)
- 28 Mar 2024 Apollomics announces intention to submit NDA to US FDA for Non-small cell lung cancer (Second-line therapy or greater) in 2026
- 29 Feb 2024 Apollomics completes meeting with US FDA for NDA submission for Vebreltinib for Non-small cell lung cancer in USA